Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with SOX as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR-OPC-17013262Phase 4Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Aug 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, tegafur and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Shanxi Cancer Hospital. Primary endpoint: progression-free survival. Started Aug 2017; status: recruiting.
02
Drugs
Rivoceranibtegafuroxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-OPC-17013262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17013262.